Journal
MOLECULAR AND CELLULAR BIOLOGY
Volume 26, Issue 6, Pages 2019-2028Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/MCB.26.6.2019-2028.2006
Keywords
-
Categories
Funding
- NCI NIH HHS [K01 CA098809, R01 CA089212, R01-CA089212, K01-CA098809] Funding Source: Medline
Ask authors/readers for more resources
Adaptation to hypoxic microenvironment is critical for tumor survival and metastatic spread. Hypoxia-inducible factor 1 alpha (HIF-1 alpha) plays a key role in this adaptation by stimulating the production of proangiogenic factors and inducing enzymes necessary for anaerobic metabolism. Histone deacetylase inhibitors (HDACIs) produce a marked inhibition of HIF-1 alpha expression and are currently in clinical trials partly based on their potent antiangiogenic effects. Although it has been postulated that HDACIs affect HIF-1 alpha expression by enhancing its interactions with VHL (von Hippel Lindau), thus promoting its ubiquitination and degradation, the actual mechanisms by which HDACIs decrease HIF-1 alpha levels are not clear. Here, we present data indicating that HDACIs induce the proteasomal degradation of HIF-1 alpha by a mechanism that is independent of VHL and p53 and does not require the ubiquitin system. This degradation pathway involves the enhanced interaction of HIF-1 alpha with HSP70 and is secondary to a disruption of the HSP70/HSP90 axis function that appears mediated by the activity of HDAC-6.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available